Mercury Biopharmaceutical Corporation
TWO: 6932.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yaoren Liang
- Employees
- 21
- Headquarters
- New Taipei City, Taiwan
- IPO year
- 2022
- Market cap
- NT$3.4B
- Website
- https://merdury.com
Loading 6932…
Loading profile data…Frequently asked questions about 6932
What does Mercury Biopharmaceutical Corporation (6932.TWO) do?
Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceu...
Where does 6932.TWO trade?
Mercury Biopharmaceutical Corporation (6932.TWO) trades on the Taipei Exchange.
What sector is 6932.TWO in?
Mercury Biopharmaceutical Corporation (6932.TWO) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Mercury Biopharmaceutical Corporation?
Yaoren Liang is the chief executive officer of Mercury Biopharmaceutical Corporation (6932.TWO).
Where is Mercury Biopharmaceutical Corporation headquartered?
Mercury Biopharmaceutical Corporation is headquartered in Taiwan.
Does 6932.TWO pay a dividend?
Mercury Biopharmaceutical Corporation (6932.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6932.TWO go public?
Mercury Biopharmaceutical Corporation (6932.TWO) completed its initial public offering in 2022.